Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term antibody response to CMV gB vaccine in liver or renal transplant candidates
2012-002767-95Phase 2Completed
- Sponsor
- University College London
- Start
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytomegalovirus subunit vaccine glycoprotein B in cytomegalovirus disease (CMV) (2 arms), sponsored by University College London. Primary endpoint: Anti-gB titre level. Started Mar 2013; status: completed.
02
Drugs
cytomegalovirus subunit vaccine glycoprotein B
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2012-002767-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002767-95.